TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.

TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.

Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals Pty Ltd today announced that its innovative hormone cream for use in postmenopausal women with hypoactive sexual desire dysfunction (HSDD) has been accepted for evaluation by the Australian Therapeutic Goods Administration (TGA).

“The acceptance of our dossier is the next step towards women gaining access to a regulated pharmacotherapy for HSDD that is female specific” said Michael Buckley, Lawley’s Medical Director. “There is a global unmet clinical need for a regulated, safe and effective treatment of postmenopausal women who experience hypoactive sexual desire dysfunction (HSDD). Australian researchers lead the world in this area of menopausal medicine and Lawley has focused our research and development in this niche area for the past 20 years.”

Hypoactive sexual desire dysfunction (HSDD) affects one in three women (32.8%) aged between 40 and 64 years of age and is a major health issue for women worldwide.

HSSD is characterised by significant loss of sexual desire, diminished sexual motivation, and the absence of sexual pleasure, fantasy and arousal which creates personal distress. HSDD is often a significant stressor in partnered relationships; postmenopausal women are most affected.